Undisclosed Program

About Zhimeng Biopharma

Clinical-stage biotech developing novel small molecules for functional cure of chronic hepatitis B and treatment of severe neurological disorders.

About Zhimeng Biopharma

Clinical-stage biotech developing novel small molecules for functional cure of chronic hepatitis B and treatment of severe neurological disorders.

About Zhimeng Biopharma

Clinical-stage biotech developing novel small molecules for functional cure of chronic hepatitis B and treatment of severe neurological disorders.

About Zhimeng Biopharma

Clinical-stage biotech developing novel small molecules for functional cure of chronic hepatitis B and treatment of severe neurological disorders.

About PMV Pharma

PMV Pharma's mission is to conquer cancer by restoring the function of the most frequently mutated tumor suppressor, p53. The company's key achievement is advancing rezatapopt, a first-in-class p53 Y220C reactivator, into a pivotal Phase 1/2 trial (PYNNACLE) with Fast Track designation and publishing compelling first-in-human data in the New England Journal of Medicine. Its strategy leverages a deep structural biology platform to develop tumor-agnostic therapies targeting specific p53 hotspot mutations, aiming to address a major unmet need in approximately 50% of all cancers.

About Crestone

Crestone is a private, clinical-stage biotech company pioneering novel mechanism-of-action antibacterial agents to combat serious and resistant infections. Its most advanced program, CRS3123, has demonstrated promising efficacy and safety in a Phase 2 trial for C. difficile infection, with results published in a top-tier journal. The company's broader pipeline targets significant public health threats like MRSA, VRE, and nontuberculous mycobacterial (NTM) disease, positioning it in the critical fight against antimicrobial resistance (AMR). Founded in 2015 by a team of experienced scientists, Crestone operates as a research-focused organization seeking investment and talent to advance its innovative portfolio.

About Crestone

Crestone is a private, clinical-stage biotech company pioneering novel mechanism-of-action antibacterial agents to combat serious and resistant infections. Its most advanced program, CRS3123, has demonstrated promising efficacy and safety in a Phase 2 trial for C. difficile infection, with results published in a top-tier journal. The company's broader pipeline targets significant public health threats like MRSA, VRE, and nontuberculous mycobacterial (NTM) disease, positioning it in the critical fight against antimicrobial resistance (AMR). Founded in 2015 by a team of experienced scientists, Crestone operates as a research-focused organization seeking investment and talent to advance its innovative portfolio.

About Crestone

Crestone is a private, clinical-stage biotech company pioneering novel mechanism-of-action antibacterial agents to combat serious and resistant infections. Its most advanced program, CRS3123, has demonstrated promising efficacy and safety in a Phase 2 trial for C. difficile infection, with results published in a top-tier journal. The company's broader pipeline targets significant public health threats like MRSA, VRE, and nontuberculous mycobacterial (NTM) disease, positioning it in the critical fight against antimicrobial resistance (AMR). Founded in 2015 by a team of experienced scientists, Crestone operates as a research-focused organization seeking investment and talent to advance its innovative portfolio.

About Calico

Calico (Calico Life Sciences LLC) is a pioneering, research-driven biotechnology company singularly focused on deciphering the biology of aging and translating those insights into novel therapeutics. Founded by Arthur D. Levinson and backed by Alphabet, it operates with a unique, long-term horizon, blending academic-style basic research in model organisms with industrial-scale drug discovery and development. Its pipeline includes several early- and clinical-stage assets targeting specific diseases of aging, supported by a robust technology platform and strategic collaborations with leading academic and industry partners.

About Neuroptika

Neuroptika is a private, preclinical biotech developing innovative treatments for retinal diseases, primarily glaucoma and age-related macular degeneration (AMD). The company's pipeline includes two lead programs: NRO-CMK, a neuroprotective gene therapy for glaucoma targeting retinal ganglion cells, and NRO-VTN, an antibody-based therapy aimed at inhibiting drusen formation in dry AMD. Founded in 2019 and led by a co-CEO team with expertise in science/IP and corporate finance, the company is positioned to address the growing global patient population with significant unmet medical needs. Neuroptika is currently in the preclinical research and development phase.

About PsiThera

PsiThera is a private, pre-clinical stage biotech aiming to disrupt the immunology market by creating oral 'antibody-in-a-pill' alternatives to injectable biologics. Its core differentiator is the QUAISAR platform, a physics-native, AI-accelerated computational engine designed to model biologically relevant protein motion and reveal transient, druggable pockets on challenging targets. The company is advancing a pipeline of early-stage programs against targets like sTNFα, mOX40L, and TL1A for conditions such as rheumatology, inflammatory bowel disease, and atopic dermatitis.

About Curemark

Curemark is a clinical-stage biotech pioneering a novel approach to neurological disorders by targeting underlying enzyme deficiencies, particularly in protein digestion. The company's lead asset, CM-AT for Autism Spectrum Disorder, has completed pivotal studies and represents a potential first-in-class treatment. Curemark's proprietary platform, which links pancreatic enzyme function to neurotransmitter production, also supports a broader pipeline targeting ADHD, addiction, Parkinson's, and schizophrenia. As a private company, its near-term success hinges on advancing CM-AT towards regulatory approval and commercialization.

About Curemark

Curemark is a clinical-stage biotech pioneering a novel approach to neurological disorders by targeting underlying enzyme deficiencies, particularly in protein digestion. The company's lead asset, CM-AT for Autism Spectrum Disorder, has completed pivotal studies and represents a potential first-in-class treatment. Curemark's proprietary platform, which links pancreatic enzyme function to neurotransmitter production, also supports a broader pipeline targeting ADHD, addiction, Parkinson's, and schizophrenia. As a private company, its near-term success hinges on advancing CM-AT towards regulatory approval and commercialization.

About Curemark

Curemark is a clinical-stage biotech pioneering a novel approach to neurological disorders by targeting underlying enzyme deficiencies, particularly in protein digestion. The company's lead asset, CM-AT for Autism Spectrum Disorder, has completed pivotal studies and represents a potential first-in-class treatment. Curemark's proprietary platform, which links pancreatic enzyme function to neurotransmitter production, also supports a broader pipeline targeting ADHD, addiction, Parkinson's, and schizophrenia. As a private company, its near-term success hinges on advancing CM-AT towards regulatory approval and commercialization.

About Curemark

Curemark is a clinical-stage biotech pioneering a novel approach to neurological disorders by targeting underlying enzyme deficiencies, particularly in protein digestion. The company's lead asset, CM-AT for Autism Spectrum Disorder, has completed pivotal studies and represents a potential first-in-class treatment. Curemark's proprietary platform, which links pancreatic enzyme function to neurotransmitter production, also supports a broader pipeline targeting ADHD, addiction, Parkinson's, and schizophrenia. As a private company, its near-term success hinges on advancing CM-AT towards regulatory approval and commercialization.

About Integral Molecular

Integral Molecular is a privately held, revenue-generating biotechnology company that has established itself as an industry leader in membrane protein and antibody discovery technologies. The company operates a dual business model, providing fee-for-service research tools and reagent platforms while also developing its own preclinical therapeutic antibody pipeline for out-licensing. Its core strength lies in tackling difficult membrane protein targets, which are implicated in a wide range of diseases but have been historically challenging for drug discovery. Recent milestones include FDA qualification progress for its Membrane Proteome Array and the advancement of several bispecific and antibody-drug conjugate candidates into preclinical development.

About Integral Molecular

Integral Molecular is a privately held, revenue-generating biotechnology company that has established itself as an industry leader in membrane protein and antibody discovery technologies. The company operates a dual business model, providing fee-for-service research tools and reagent platforms while also developing its own preclinical therapeutic antibody pipeline for out-licensing. Its core strength lies in tackling difficult membrane protein targets, which are implicated in a wide range of diseases but have been historically challenging for drug discovery. Recent milestones include FDA qualification progress for its Membrane Proteome Array and the advancement of several bispecific and antibody-drug conjugate candidates into preclinical development.

About Octant Biotech

Octant Biotech is a private, pre-revenue drug discovery company pioneering a platform-based approach to engineer small molecule drugs against complex cellular mechanisms. Its core technology, the Octant Navigator, integrates Generative Biology (high-throughput cellular sensor engineering), Generative Chemistry (nano-scale automated synthesis), and Generative AI in a rapid design-build-test-learn cycle. The company has built a diversified preclinical pipeline targeting genetic, oncology, metabolism, and immunology diseases, with its most advanced candidate, OCT-980 for retinitis pigmentosa, having initiated a Phase 1a study in healthy volunteers in Q1 2026.

About Octant Biotech

Octant Biotech is a private, pre-revenue drug discovery company pioneering a platform-based approach to engineer small molecule drugs against complex cellular mechanisms. Its core technology, the Octant Navigator, integrates Generative Biology (high-throughput cellular sensor engineering), Generative Chemistry (nano-scale automated synthesis), and Generative AI in a rapid design-build-test-learn cycle. The company has built a diversified preclinical pipeline targeting genetic, oncology, metabolism, and immunology diseases, with its most advanced candidate, OCT-980 for retinitis pigmentosa, having initiated a Phase 1a study in healthy volunteers in Q1 2026.

About Octant Biotech

Octant Biotech is a private, pre-revenue drug discovery company pioneering a platform-based approach to engineer small molecule drugs against complex cellular mechanisms. Its core technology, the Octant Navigator, integrates Generative Biology (high-throughput cellular sensor engineering), Generative Chemistry (nano-scale automated synthesis), and Generative AI in a rapid design-build-test-learn cycle. The company has built a diversified preclinical pipeline targeting genetic, oncology, metabolism, and immunology diseases, with its most advanced candidate, OCT-980 for retinitis pigmentosa, having initiated a Phase 1a study in healthy volunteers in Q1 2026.

About Octant Biotech

Octant Biotech is a private, pre-revenue drug discovery company pioneering a platform-based approach to engineer small molecule drugs against complex cellular mechanisms. Its core technology, the Octant Navigator, integrates Generative Biology (high-throughput cellular sensor engineering), Generative Chemistry (nano-scale automated synthesis), and Generative AI in a rapid design-build-test-learn cycle. The company has built a diversified preclinical pipeline targeting genetic, oncology, metabolism, and immunology diseases, with its most advanced candidate, OCT-980 for retinitis pigmentosa, having initiated a Phase 1a study in healthy volunteers in Q1 2026.

About Octant Biotech

Octant Biotech is a private, pre-revenue drug discovery company pioneering a platform-based approach to engineer small molecule drugs against complex cellular mechanisms. Its core technology, the Octant Navigator, integrates Generative Biology (high-throughput cellular sensor engineering), Generative Chemistry (nano-scale automated synthesis), and Generative AI in a rapid design-build-test-learn cycle. The company has built a diversified preclinical pipeline targeting genetic, oncology, metabolism, and immunology diseases, with its most advanced candidate, OCT-980 for retinitis pigmentosa, having initiated a Phase 1a study in healthy volunteers in Q1 2026.

About Octant Biotech

Octant Biotech is a private, pre-revenue drug discovery company pioneering a platform-based approach to engineer small molecule drugs against complex cellular mechanisms. Its core technology, the Octant Navigator, integrates Generative Biology (high-throughput cellular sensor engineering), Generative Chemistry (nano-scale automated synthesis), and Generative AI in a rapid design-build-test-learn cycle. The company has built a diversified preclinical pipeline targeting genetic, oncology, metabolism, and immunology diseases, with its most advanced candidate, OCT-980 for retinitis pigmentosa, having initiated a Phase 1a study in healthy volunteers in Q1 2026.

About Concentric Analgesics

Concentric Analgesics is a clinical-stage biotech developing a novel platform of non-opioid pain therapeutics. Its lead candidate, vocacapsaicin (CA-008), is a Phase 3-ready prodrug that converts to capsaicin to provide durable, localized pain relief without systemic side effects or numbness. The company aims to address significant unmet needs in postsurgical and chronic pain markets, targeting the reduction of opioid dependence and associated healthcare costs. Its pipeline also includes programs for cancer-related pain and osteoarthritis.

About Eleva

Eleva Biologics is a German, clinical-stage biotech leveraging a proprietary moss-based platform to develop novel biologics and cell therapies considered inaccessible by conventional systems. The company has built a pipeline initially targeting complement disorders and enzyme replacement therapies, with two candidates already in clinical development. Led by an experienced team, Eleva operates as a private, pre-revenue entity aiming to establish a broad portfolio of unique product candidates, both independently and through partnerships.

About Eleva

Eleva Biologics is a German, clinical-stage biotech leveraging a proprietary moss-based platform to develop novel biologics and cell therapies considered inaccessible by conventional systems. The company has built a pipeline initially targeting complement disorders and enzyme replacement therapies, with two candidates already in clinical development. Led by an experienced team, Eleva operates as a private, pre-revenue entity aiming to establish a broad portfolio of unique product candidates, both independently and through partnerships.

About Behavioral Pharma

Behavioral Pharma operates at the intersection of neuroscience and digital health, aiming to address the significant unmet needs in mental healthcare. The company's strategy involves developing a hybrid therapeutic platform that pairs software-based interventions with traditional drug mechanisms, potentially improving efficacy, adherence, and outcomes. As a private, early-stage company likely in pre-clinical or early clinical development, it targets a large and growing market but faces challenges typical of biotech startups, including funding, clinical validation, and competition. Its success will hinge on demonstrating the synergistic value of its combined digital-pharmacological approach.

About EnnoDC

EnnoDC is an innovative biotech developing first-in-class, dendritic cell-targeting immunotherapies. Its core technology, the 'DC engager' platform, creates bispecific antibodies that co-engage CD40 for dendritic cell activation and a disease-specific antigen for priming, effectively functioning as an in vivo 'Antibody Mediated Vaccine' (AMV). The company has validated its approach in early infectious disease trials and is now advancing a dynamic pipeline of five candidates, with a strategic presence in both Paris and Cambridge, Massachusetts. EnnoDC represents a compelling player in the next wave of immunotherapies aiming to combine the precision of checkpoint modulators with the durable memory of vaccines.

About EnnoDC

EnnoDC is an innovative biotech developing first-in-class, dendritic cell-targeting immunotherapies. Its core technology, the 'DC engager' platform, creates bispecific antibodies that co-engage CD40 for dendritic cell activation and a disease-specific antigen for priming, effectively functioning as an in vivo 'Antibody Mediated Vaccine' (AMV). The company has validated its approach in early infectious disease trials and is now advancing a dynamic pipeline of five candidates, with a strategic presence in both Paris and Cambridge, Massachusetts. EnnoDC represents a compelling player in the next wave of immunotherapies aiming to combine the precision of checkpoint modulators with the durable memory of vaccines.

About EnnoDC

EnnoDC is an innovative biotech developing first-in-class, dendritic cell-targeting immunotherapies. Its core technology, the 'DC engager' platform, creates bispecific antibodies that co-engage CD40 for dendritic cell activation and a disease-specific antigen for priming, effectively functioning as an in vivo 'Antibody Mediated Vaccine' (AMV). The company has validated its approach in early infectious disease trials and is now advancing a dynamic pipeline of five candidates, with a strategic presence in both Paris and Cambridge, Massachusetts. EnnoDC represents a compelling player in the next wave of immunotherapies aiming to combine the precision of checkpoint modulators with the durable memory of vaccines.

About PinCell

PinCell is an Italian, private biotech company targeting orphan dermatological diseases through novel anti-inflammatory pathways. The company leverages deep academic roots and expertise in cutaneous biology, with a leadership team combining clinical dermatology, research, and biotech management. Currently in the pre-clinical stage, PinCell aims to develop groundbreaking treatments for conditions like pemphigus, operating in a niche with limited competition and significant unmet need. Its foundation is built on proprietary research from its founders' laboratories.

About Topas Therapeutics

Topas Therapeutics is a clinical-stage biotech pioneering a targeted approach to immune tolerance using its proprietary Topas Particle Conjugates (TPCs). The platform leverages liver sinusoidal endothelial cells (LSECs) to deliver disease-specific antigens, aiming to reprogram the immune system and induce durable, antigen-specific tolerance via regulatory T cells (Tregs). With clinical proof-of-concept established in a Phase 2a celiac disease trial, the company is preparing for a global Phase 2b study and is positioned to address a broad spectrum of autoimmune conditions with high unmet need. Its technology offers a potentially disease-modifying alternative to broad immunosuppression.

About Wayfinder Biosciences

Wayfinder Biosciences is an early-stage biotech developing RNA-targeting small molecules to address undruggable disease targets. The company's platform integrates RNA-based sensors and AI/ML to discover compounds that bind to specific mRNA structures, halting protein production before it begins. Its initial pipeline focuses on high-value targets in oncology and neurodegeneration. As a private, pre-revenue company, Wayfinder is building its foundational platform and asset pipeline while seeking partnerships to expand into broader therapeutic areas.

About Orano med

Orano Med is a clinical-stage biotech pioneering targeted alpha therapy (TAT) with lead-212, a highly potent but short-range alpha emitter designed to precisely destroy cancer cells while sparing healthy tissue. The company has built an integrated platform encompassing isotope production, preclinical development, and has initiated clinical trials. With operations in the US and France, Orano Med is positioning itself in the rapidly growing radioligand therapy market, aiming to address significant unmet needs in oncology.

About Tenpoint Therapeutics

Tenpoint Therapeutics is a private, clinical-stage biotech developing novel treatments for age-related vision decline, with a lead program in presbyopia. The company's strategy centers on addressing key unmet needs in functional near vision, duration of effect, and tolerability for daily use. With its lead asset, BRIMOCHOL™ PF, having achieved an FDA New Drug Application (NDA) acceptance, Tenpoint is positioned for a potential near-term commercial launch in a large, underserved market. The company represents a specialized player in the ophthalmology space, aiming to set a new standard in presbyopia care.

About Tenpoint Therapeutics

Tenpoint Therapeutics is a private, clinical-stage biotech developing novel treatments for age-related vision decline, with a lead program in presbyopia. The company's strategy centers on addressing key unmet needs in functional near vision, duration of effect, and tolerability for daily use. With its lead asset, BRIMOCHOL™ PF, having achieved an FDA New Drug Application (NDA) acceptance, Tenpoint is positioned for a potential near-term commercial launch in a large, underserved market. The company represents a specialized player in the ophthalmology space, aiming to set a new standard in presbyopia care.

About Ability Biotherapeutics

AI‑driven platform developer creates conditional, multispecific antibodies for cancer and autoimmune disease.

About bioarctic-ab

BioArctic AB is a research-intensive Swedish biopharma focused on translating novel insights into protein aggregation pathology into transformative treatments for neurodegenerative diseases. Its strategic triumph is the Eisai-partnered anti-amyloid beta protofibril antibody lecanemab (Leqembi®), which achieved FDA approval in 2023, validating the company's core scientific thesis. The company's strategy balances revenue from this landmark partnership with advancing a wholly-owned pipeline targeting alpha-synuclein in Parkinson's disease, leveraging its proprietary BrainTransporter® platform to enhance drug delivery to the brain. With a market cap nearing $28 billion, BioArctic stands as a premier European biotech success story.

About Scholar Rock Holding

Scholar Rock is a clinical-stage biopharmaceutical company founded on a paradigm-shifting scientific strategy: targeting the latent, inactive forms of growth factors, particularly within the TGFβ superfamily, to achieve precise, localized therapeutic effects. The company's most advanced asset, apitegromab, has demonstrated promising Phase 3 results in spinal muscular atrophy (SMA) and is positioned as a potential first-in-class muscle-targeted therapy. Supported by a robust proprietary platform and a strong financial position, Scholar Rock's strategy extends beyond neuromuscular diseases into cardiometabolic disorders and immuno-oncology, aiming to build a diversified portfolio of novel biologics.

About CRISPR Therapeutics

CRISPR Therapeutics' mission is to develop curative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its landmark achievement is the approval of CASGEVY™ (exa-cel), the world's first CRISPR-based therapy, developed with Vertex Pharmaceuticals for sickle cell disease and beta thalassemia. The company's strategy leverages a fully integrated R&D and manufacturing infrastructure to advance a diversified clinical pipeline, including allogeneic CAR-T therapies for oncology and programs in regenerative medicine. CRISPR Therapeutics aims to sustain its first-mover advantage by expanding the applications of gene editing across multiple therapeutic areas.

About CRISPR Therapeutics

CRISPR Therapeutics' mission is to develop curative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its landmark achievement is the approval of CASGEVY™ (exa-cel), the world's first CRISPR-based therapy, developed with Vertex Pharmaceuticals for sickle cell disease and beta thalassemia. The company's strategy leverages a fully integrated R&D and manufacturing infrastructure to advance a diversified clinical pipeline, including allogeneic CAR-T therapies for oncology and programs in regenerative medicine. CRISPR Therapeutics aims to sustain its first-mover advantage by expanding the applications of gene editing across multiple therapeutic areas.

About CRISPR Therapeutics

CRISPR Therapeutics' mission is to develop curative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its landmark achievement is the approval of CASGEVY™ (exa-cel), the world's first CRISPR-based therapy, developed with Vertex Pharmaceuticals for sickle cell disease and beta thalassemia. The company's strategy leverages a fully integrated R&D and manufacturing infrastructure to advance a diversified clinical pipeline, including allogeneic CAR-T therapies for oncology and programs in regenerative medicine. CRISPR Therapeutics aims to sustain its first-mover advantage by expanding the applications of gene editing across multiple therapeutic areas.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals is pioneering a TechBio approach to industrialize drug discovery, leveraging its proprietary Recursion OS—a closed-loop platform integrating automated wet labs, one of the world's largest fit-for-purpose biological datasets (>50 PB), and machine learning foundation models. The company has built a maturing clinical pipeline, with its lead asset, REC-4881 for Familial Adenomatous Polyposis (FAP), in Phase 2 and multiple other oncology programs in Phase 1/2. Its strategy centers on scaling its platform to systematically discover and develop first-in-class and best-in-class medicines, supported by strategic partnerships with pharmaceutical and technology leaders.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals is pioneering a TechBio approach to industrialize drug discovery, leveraging its proprietary Recursion OS—a closed-loop platform integrating automated wet labs, one of the world's largest fit-for-purpose biological datasets (>50 PB), and machine learning foundation models. The company has built a maturing clinical pipeline, with its lead asset, REC-4881 for Familial Adenomatous Polyposis (FAP), in Phase 2 and multiple other oncology programs in Phase 1/2. Its strategy centers on scaling its platform to systematically discover and develop first-in-class and best-in-class medicines, supported by strategic partnerships with pharmaceutical and technology leaders.

About uniQure

uniQure's mission is to reimagine the future of medicine by delivering innovative, potentially curative gene therapies for severe genetic and neurodegenerative diseases. The company's strategic foundation is its industry-leading, modular AAV5 platform, which has demonstrated a validated safety profile and holds exclusive rights for therapeutic delivery to the brain and liver. Its most advanced program, AMT-130 for Huntington's disease, represents a potential first-in-class treatment, positioning uniQure at the forefront of CNS gene therapy with a pipeline targeting high-unmet-need indications.

About Tectonic Therapeutic

Tectonic Therapeutic is a clinical-stage biotech focused on unlocking the vast therapeutic potential of G-Protein Coupled Receptors (GPCRs) through its proprietary GEODe™ platform for biologic drug discovery. Founded on foundational research from Harvard Medical School and led by a deeply experienced pharmaceutical R&D team, the company's mission is to develop transformative medicines for cardiopulmonary and fibrotic diseases. Its strategy centers on advancing its lead Fc-relaxin fusion program, TX000045, through clinical proof-of-concept while leveraging its platform to build a pipeline of novel GPCR-targeted biologics.

About PMV Pharmaceuticals

PMV Pharmaceuticals' mission is to conquer cancer by correcting the function of mutant p53, the most frequently altered tumor suppressor in human oncology. The company's core achievement is advancing rezatapopt (PC14586), a first-in-class p53 Y220C reactivator, into the pivotal PYNNACLE Phase 1/2 study, with data recently published in the New England Journal of Medicine demonstrating proof-of-concept. Its strategy integrates a mutation-focused, tumor-agnostic development path with a deep pipeline targeting additional p53 hotspot mutations, aiming to establish a new class of precision oncology therapeutics. PMV operates as a publicly traded entity, building upon over four decades of foundational p53 research co-discovered by its scientific founder.

Therapeutic Areas